Brief: FDA Agrees With Galmed's Plan To Use Aramchol Meglumine

Eocene

02/08/2021 12:33

Aug 2 (Reuters) - Galmed Pharmaceuticals Ltd  GLMD.O :
    * FDA AGREES WITH GALMED'S PLAN TO USE ARAMCHOL MEGLUMINE IN
THE
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PART OF THE PHASE 3
ARMOR STUDY
    * GALMED PHARMACEUTICALS LTD - FDA SUPPORTED CO'S LIMITED
CLINICAL
PHARMACOLOGY STUDY PLAN WITH RESPECT TO ARAMCHOL MEGLUMINE
    * GALMED- INITIATION OF RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED PART OF PHASE 3 STUDY WILL BE CONDUCTED WITH
ARAMCHOL MEGLUMINE ONCE DAILY REGIMEN

Source text for Eikon:  ID:nPn81J07Da 
Further company coverage:  GLMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))